Dr. D. Lansing Taylor (Drug Discovery Institute and Dept of Computational and Systems Biology), along with Dr. Vijay Yechoor (Department of Medicine and Director, Diabetes and Beta Cell Biology Center) have received a one year funded initiative to study the effects of COVID-19 on the Diabetic Liver. This initiative is a funded supplement to the grant: “Human Microphysiology Systems Disease Model of Type 2 Diabetes Starting with Liver and pancreatic Islets”

Dr. D. Lansing Taylor (Drug Discovery Institute and Dept of Computational and Systems Biology),  along with Dr. Vijay Yechoor (Department of Medicine and Director, Diabetes and Beta Cell Biology Center) have received a one year funded initiative to study the effects of COVID-19 on the Diabetic Liver.  This initiative is a funded supplement to the grant: “Human Microphysiology Systems Disease Model of Type 2 Diabetes Starting with Liver and pancreatic Islets”

The COVID-19 pandemic requires a rapid response to find therapeutic strategies for T2D patients who have a much higher mortality than non-diabetics. Therefore, there is a need for therapeutic strategies to mitigate the cytokine storm syndrome (CSS) and thethrombotic micro-angiopathy (TMA)that are prevalentin these patients. Our normal-fasting and T2D vLAMPS models developed during the UG3 period of the parent funding are ready to be applied to this challenge when human macrophages are infected with SARS-CoV-2 and flowed into the vascular channel of the vLAMPS.

WordPress Image Lightbox Plugin